{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T09:20:52Z","timestamp":1777540852242,"version":"3.51.4"},"reference-count":59,"publisher":"Consilium Medicum","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ter. arkh."],"published-print":{"date-parts":[[2014]]},"DOI":"10.17116\/terarkh20148612127-134","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T17:07:12Z","timestamp":1460653632000},"page":"127","source":"Crossref","is-referenced-by-count":4,"title":["Mastocytosis. Review of the literature and description of clinical cases"],"prefix":"10.26442","volume":"86","author":[{"given":"A. L.","family":"Melikian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. N.","family":"Subortseva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. R.","family":"Goriacheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. I.","family":"Koloshe\u012dnova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. V.","family":"Vakhrusheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. M.","family":"Kovrigina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. B.","family":"Sudarikov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V. N.","family":"Dvirnyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. N.","family":"Obukhova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18344","reference":[{"key":"key-10.17116\/terarkh20148612127-134-1","unstructured":"Horny H.P., Metcalfe D.D., Bennett J.M. et al. Mastocytosis. In: Swerdlow S.H., Campo E., Harris N.L. et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: World Health Organization 2008: 54-63."},{"key":"key-10.17116\/terarkh20148612127-134-2","doi-asserted-by":"crossref","unstructured":"Valent P., Akin C., Escribano L. et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007; 37 (6): 435-453.","DOI":"10.1111\/j.1365-2362.2007.01807.x"},{"key":"key-10.17116\/terarkh20148612127-134-3","doi-asserted-by":"crossref","unstructured":"Orfao A., Garcia-Montero A.C., Sanchez L. et al. REMA. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007; 138 (1): 12-30.","DOI":"10.1111\/j.1365-2141.2007.06619.x"},{"key":"key-10.17116\/terarkh20148612127-134-4","unstructured":"De la Hoz B., Gonz\u00e1lez de Olano D., Alvarez I. et al. Gu\u00edas cl\u00ednicas para el diagn\u00f3stico, tratamiento y seguimiento de las mastocitosis [Guidelines for the diagnosis, treatment and management of mastocytosis]. An Sist Sanit Navar 2008; 31 (1): 11-32."},{"key":"key-10.17116\/terarkh20148612127-134-5","doi-asserted-by":"crossref","unstructured":"Pardanani A., Akin C., Valent P. Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 2006; 19 (3): 595-615.","DOI":"10.1016\/j.beha.2005.07.010"},{"key":"key-10.17116\/terarkh20148612127-134-6","doi-asserted-by":"crossref","unstructured":"Metcalfe D.D. Mast cells and mastocytosis. Blood 2008; 112 (4): 946-956.","DOI":"10.1182\/blood-2007-11-078097"},{"key":"key-10.17116\/terarkh20148612127-134-7","doi-asserted-by":"crossref","unstructured":"Castells M., Metcalfe D.D., Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011; 12 (4): 259-270.","DOI":"10.2165\/11588890-000000000-00000"},{"key":"key-10.17116\/terarkh20148612127-134-8","doi-asserted-by":"crossref","unstructured":"Wolff K., Komar M., Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 2001; 25 (7): 519-528.","DOI":"10.1016\/S0145-2126(01)00044-3"},{"key":"key-10.17116\/terarkh20148612127-134-9","doi-asserted-by":"crossref","unstructured":"Valent P., Horny H.P., Escribano L. et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001; 25 (7): 603-625.","DOI":"10.1016\/S0145-2126(01)00038-8"},{"key":"key-10.17116\/terarkh20148612127-134-10","doi-asserted-by":"crossref","unstructured":"Alvarez-Twose I., Morgado J.M., S\u00e1nchez-Mu\u00f1oz L. et al. Current state of biology and diagnosis of clonal mast cell diseases in adults. Int J Lab Hematol 2012; 34 (5): 445-460.","DOI":"10.1111\/j.1751-553X.2012.01427.x"},{"key":"key-10.17116\/terarkh20148612127-134-11","doi-asserted-by":"crossref","unstructured":"Ma H.B., Xu X., Liu W.P. et al. Successful treatment of mast cell sarcoma of the uterus with imatinib. Int J Hematol 2011; 94 (5): 491-494.","DOI":"10.1007\/s12185-011-0952-2"},{"key":"key-10.17116\/terarkh20148612127-134-12","doi-asserted-by":"crossref","unstructured":"Bugalia A., Abraham A., Balasubramanian P. et al. Mast cell sarcoma of the small intestine: a case report. J Clin Pathol 2011; 64 (11): 1035-1037.","DOI":"10.1136\/jclinpath-2011-200154"},{"key":"key-10.17116\/terarkh20148612127-134-13","doi-asserted-by":"crossref","unstructured":"Brci\u0107 L., Vuleti\u0107 L.B., Stepan J. et al. Mast-cell sarcoma of the tibia. J Clin Pathol 2007; 60 (4): 424-425.","DOI":"10.1136\/jcp.2006.040857"},{"key":"key-10.17116\/terarkh20148612127-134-14","doi-asserted-by":"crossref","unstructured":"Auquit-Auckbur I., Lazar C., Deneuve S. et al. Malignant transformation of mastocytoma developed on skin mastocytosis into cutaneous mast cell sarcoma. Am J Surg Pathol 2012; 36 (5): 779-782.","DOI":"10.1097\/PAS.0b013e31824c0d92"},{"key":"key-10.17116\/terarkh20148612127-134-15","doi-asserted-by":"crossref","unstructured":"Akin C., Scott L.M., Kocabas C.N. et al. Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \"idiopathic\" anaphylaxis. Blood 2007; 110 (7): 2331-2333.","DOI":"10.1182\/blood-2006-06-028100"},{"key":"key-10.17116\/terarkh20148612127-134-16","doi-asserted-by":"crossref","unstructured":"Valent P., Akin C., Arock M. et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012; 157 (3): 215-225.","DOI":"10.1159\/000328760"},{"key":"key-10.17116\/terarkh20148612127-134-17","doi-asserted-by":"crossref","unstructured":"Alvarez-Twose I., Gonz\u00e1lez de Olano D., S\u00e1nchez-Mu\u00f1oz L. et al. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms. J Allergy Clin Immunol 2010; 125 (6): 1269-1278.","DOI":"10.1016\/j.jaci.2010.02.019"},{"key":"key-10.17116\/terarkh20148612127-134-18","doi-asserted-by":"crossref","unstructured":"Akin C., Fumo G., Yavuz A.S. et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004; 103 (8): 3222-3225.","DOI":"10.1182\/blood-2003-11-3816"},{"key":"key-10.17116\/terarkh20148612127-134-19","doi-asserted-by":"crossref","unstructured":"Alvarez-Twose I., Gonz\u00e1lez P., Morgado J.M. et al. Complete response after imatinibmesylate therapy in a patient with well-differentiated systemic mastocytosis. J Clin Oncol 2012; 30 (12): e126-129.","DOI":"10.1200\/JCO.2011.38.9973"},{"key":"key-10.17116\/terarkh20148612127-134-20","doi-asserted-by":"crossref","unstructured":"Valent P., Samorapoompichit P., Sperr W.R. et al. Myelomastocytic leukemia: myeloid neoplasm characterized by partial differentiation of mast cell-lineage cells. Hematol J 2002; 3 (2): 90-94.","DOI":"10.1038\/sj.thj.6200164"},{"key":"key-10.17116\/terarkh20148612127-134-21","doi-asserted-by":"crossref","unstructured":"Arredondo A.R., Gotlib J., Shier L. et al. Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge. Am J Hematol 2010; 85 (8): 600-606.","DOI":"10.1002\/ajh.21713"},{"key":"key-10.17116\/terarkh20148612127-134-22","doi-asserted-by":"crossref","unstructured":"Sperr W.R., Escribano L., Jordan J.H. et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 2001; 25 (7): 529-536.","DOI":"10.1016\/S0145-2126(01)00041-8"},{"key":"key-10.17116\/terarkh20148612127-134-23","doi-asserted-by":"crossref","unstructured":"Horny H.P., Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001; 25 (7): 543-551.","DOI":"10.1016\/S0145-2126(01)00021-2"},{"key":"key-10.17116\/terarkh20148612127-134-24","doi-asserted-by":"crossref","unstructured":"Horny H.P., Sotlar K., Stellmacher F. et al. The tryptase positive compact round cell infiltrate of the bone marrow (TROCI-BM): a novel histopathological finding requiring the application of lineage specific markers. J Clin Pathol 2006; 59 (3): 298-302.","DOI":"10.1136\/jcp.2005.028738"},{"key":"key-10.17116\/terarkh20148612127-134-25","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Mu\u00f1oz L., Alvarez-Twose I., Garc\u00eda-Montero A.C. et al. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 2011; 24 (9): 1157-1168.","DOI":"10.1038\/modpathol.2011.84"},{"key":"key-10.17116\/terarkh20148612127-134-26","doi-asserted-by":"crossref","unstructured":"Horny H.P., Sotlar K., Valent P. Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review. Pathobiology 2010; 77 (4): 169-180.","DOI":"10.1159\/000305552"},{"key":"key-10.17116\/terarkh20148612127-134-27","doi-asserted-by":"crossref","unstructured":"Falc\u00e3o R.P., Rizzatti E.G., Saggioro F.P. et al. Flow cytometry characterization of leukemic phase of nasal NK\/T-cell lymphoma in tumor biopsies and peripheral blood. Haematologica 2007; 92 (2): e24-25.","DOI":"10.3324\/haematol.10654"},{"key":"key-10.17116\/terarkh20148612127-134-28","doi-asserted-by":"crossref","unstructured":"Sandes A.F., Castro I.N., Miura T.E. et al. Bone marrow infiltration by cells resembling plasmablasts in a patient with blasticplasmacytoid dendritic cell neoplasm. J Hematopathol 2011; 4 (2): 123-126.","DOI":"10.1007\/s12308-011-0097-5"},{"key":"key-10.17116\/terarkh20148612127-134-29","doi-asserted-by":"crossref","unstructured":"Sandes A.F., Yamamoto M., Matarraz S. et al. Altered immunophenotypic features of peripheral blood platelets in myelodysplastic syndromes. Haematologica 2012; 97 (6): 895-902.","DOI":"10.3324\/haematol.2011.057158"},{"key":"key-10.17116\/terarkh20148612127-134-30","doi-asserted-by":"crossref","unstructured":"Rizzatti E.G., Portieres F.L., Martins S.L. et al. Microgranular and t(11;17)\/PLZFRARalpha variants of acute promyelocytic leukemia also present the flow cytometric pattern of CD13, CD34, and CD15 expression characteristic of PML-RARalpha gene rearrangement. Am J Hematol 2004; 76 (1): 44-51.","DOI":"10.1002\/ajh.20055"},{"key":"key-10.17116\/terarkh20148612127-134-31","unstructured":"Matos D.M., Rizzatti E.G., Fernandes M. et al. Gammadelta and alphabeta T-cell acute lymphoblastic leukemia: comparison of their clinical and immunophenotypic features. Haematologica 2005; 90 (2): 264-266."},{"key":"key-10.17116\/terarkh20148612127-134-32","doi-asserted-by":"crossref","unstructured":"Escribano L., Diaz-Agustin B., Lopez A. et al. Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom 2004; 58 (1): 1-8.","DOI":"10.1002\/cyto.b.10072"},{"key":"key-10.17116\/terarkh20148612127-134-33","doi-asserted-by":"crossref","unstructured":"Teodosio C., Garcia-Montero A.C., Jara-Acevedo M. et al. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol 2010; 125 (3): 719-726, 726.e1-726.e4.","DOI":"10.1016\/j.jaci.2009.10.020"},{"key":"key-10.17116\/terarkh20148612127-134-34","doi-asserted-by":"crossref","unstructured":"Sanchez-Munoz L., Teodosio C., Morgado J.M. et al. Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders. Methods Cell Biol 2011; 103: 333-359.","DOI":"10.1016\/B978-0-12-385493-3.00014-0"},{"key":"key-10.17116\/terarkh20148612127-134-35","doi-asserted-by":"crossref","unstructured":"Teodosio C., Garcia-Montero A.C., Jara-Acevedo M. et al. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis. Leukemia 2012; 26 (5): 951-958.","DOI":"10.1038\/leu.2011.293"},{"key":"key-10.17116\/terarkh20148612127-134-36","doi-asserted-by":"crossref","unstructured":"Morgado J.M., Sanchez-Munoz L., Teodosio C.G. et al. Immunophenotyping in systemic mastocytosis diagnosis: eCD25 positive of alone is more informative than the eCD25 and\/or CD2 of WHO criterion. Mod Pathol 2012; 25 (4): 516-521.","DOI":"10.1038\/modpathol.2011.192"},{"key":"key-10.17116\/terarkh20148612127-134-37","doi-asserted-by":"crossref","unstructured":"Valent P., Cerny-Reiterer S., Herrmann H. et al. Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. Best Pract Res Clin Haematol 2010; 23 (3): 369-378.","DOI":"10.1016\/j.beha.2010.07.003"},{"key":"key-10.17116\/terarkh20148612127-134-38","doi-asserted-by":"crossref","unstructured":"Hauswirth A.W., Escribano L., Prados A. et al. CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking. Int J Immunopathol Pharmacol 2008; 21 (4): 797-806.","DOI":"10.1177\/039463200802100404"},{"key":"key-10.17116\/terarkh20148612127-134-39","doi-asserted-by":"crossref","unstructured":"Valent P., Sotlar K., Horny H.P. Aberrant expression of CD30 in aggressive systemic mastocytosis and mast cell leukemia: a differential diagnosis to consider in aggressive hematopoietic CD30-positive neoplasms. Leuk Lymphoma 2011; 52 (5): 740-744.","DOI":"10.3109\/10428194.2010.550072"},{"key":"key-10.17116\/terarkh20148612127-134-40","doi-asserted-by":"crossref","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87 (4): 401-411.","DOI":"10.1002\/ajh.23459"},{"key":"key-10.17116\/terarkh20148612127-134-41","doi-asserted-by":"crossref","unstructured":"Sperr W.R., Jordan J.H., Fiegl M. et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 2002; 128 (2): 136-141.","DOI":"10.1159\/000059404"},{"key":"key-10.17116\/terarkh20148612127-134-42","doi-asserted-by":"crossref","unstructured":"Garcia-Montero A.C., Jara-Acevedo M., Teodosio C. et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006; 108 (7): 2366-2372.","DOI":"10.1182\/blood-2006-04-015545"},{"key":"key-10.17116\/terarkh20148612127-134-43","doi-asserted-by":"crossref","unstructured":"Pardanani A. Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management. Am J Hematol 2011; 86 (4): 362-371.","DOI":"10.1002\/ajh.21982"},{"key":"key-10.17116\/terarkh20148612127-134-44","doi-asserted-by":"crossref","unstructured":"Arefi M., Garcia J.L., Penarrubia M.J. et al. Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement. Eur J Haematol 2012; 89 (1): 37-41.","DOI":"10.1111\/j.1600-0609.2012.01799.x"},{"key":"key-10.17116\/terarkh20148612127-134-45","doi-asserted-by":"crossref","unstructured":"Valent P., Sperr W.R., Akin C. How I treat patients with advanced systemic mastocytosis. Blood 2010; 116 (26): 5812-5817.","DOI":"10.1182\/blood-2010-08-292144"},{"key":"key-10.17116\/terarkh20148612127-134-46","doi-asserted-by":"crossref","unstructured":"Lim K.H., Pardanani A., Butterfield J.H. et al. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinibmesylate or 2-chlorodeoxyadenosine. Am J Hematol 2009; 84 (12): 790-794.","DOI":"10.1002\/ajh.21561"},{"key":"key-10.17116\/terarkh20148612127-134-47","doi-asserted-by":"crossref","unstructured":"Kluin-Nelemans H.C., Oldhoff J.M., Van Doormaal J.J. et al. Cladribine therapy for systemic mastocytosis. Blood 2003; 102 (13): 4270-4276.","DOI":"10.1182\/blood-2003-05-1699"},{"key":"key-10.17116\/terarkh20148612127-134-48","doi-asserted-by":"crossref","unstructured":"Hauswirth A.W., Simonitsch-Klupp I., Uffmann M. et al. Response totherapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 2004; 28 (3): 249-257.","DOI":"10.1016\/S0145-2126(03)00259-5"},{"key":"key-10.17116\/terarkh20148612127-134-49","doi-asserted-by":"crossref","unstructured":"Pardanani A., Tefferi A. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature. Curr Opin Hematol 2010; 17 (2): 125-132.","DOI":"10.1097\/MOH.0b013e3283366c59"},{"key":"key-10.17116\/terarkh20148612127-134-50","doi-asserted-by":"crossref","unstructured":"Bjerrum O.W. Interferon-\u03bb treatment in systemic mastocytosis. Curr Drug Targets 2011; 12 (3): 433-436.","DOI":"10.2174\/138945011794815293"},{"key":"key-10.17116\/terarkh20148612127-134-51","doi-asserted-by":"crossref","unstructured":"Ustun C., DeRemer D.L., Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res 2011; 35 (9): 1143-1152.","DOI":"10.1016\/j.leukres.2011.05.006"},{"key":"key-10.17116\/terarkh20148612127-134-52","doi-asserted-by":"crossref","unstructured":"Vega-Ruiz A., Cortes J.E., Sever M. et al. Phase II study of imatinibmesylate as therapy for patients with systemic mastocytosis. Leuk Res 2009; 33 (11): 1481-1484.","DOI":"10.1016\/j.leukres.2008.12.020"},{"key":"key-10.17116\/terarkh20148612127-134-53","doi-asserted-by":"crossref","unstructured":"Shah N.P., Lee F.Y., Luo R. et al. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006; 108 (1): 286-291.","DOI":"10.1182\/blood-2005-10-3969"},{"key":"key-10.17116\/terarkh20148612127-134-54","doi-asserted-by":"crossref","unstructured":"Verstovsek S., Tefferi A., Cortes J. et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008; 14 (12): 3906-3915.","DOI":"10.1158\/1078-0432.CCR-08-0366"},{"key":"key-10.17116\/terarkh20148612127-134-55","doi-asserted-by":"crossref","unstructured":"Gleixner K.V., Mayerhofer M., Aichberger K.J. et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816Vmutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006; 107 (2): 752-759.","DOI":"10.1182\/blood-2005-07-3022"},{"key":"key-10.17116\/terarkh20148612127-134-56","doi-asserted-by":"crossref","unstructured":"Barete S., Assous N., de Gennes C. et al. Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 2010; 69 (10): 1838-1841.","DOI":"10.1136\/ard.2009.124511"},{"key":"key-10.17116\/terarkh20148612127-134-57","doi-asserted-by":"crossref","unstructured":"Nakamura R., Chakrabarti S., Akin C. et al. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. Bone Marrow Transplant 2006; 37 (4): 353-358.","DOI":"10.1038\/sj.bmt.1705245"},{"key":"key-10.17116\/terarkh20148612127-134-58","doi-asserted-by":"crossref","unstructured":"Spyridonidis A., Thomas A.K., Bertz H. et al. Evidence for a graft-versusmast-cell effect after allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34 (6): 515-519.","DOI":"10.1038\/sj.bmt.1704627"},{"key":"key-10.17116\/terarkh20148612127-134-59","doi-asserted-by":"crossref","unstructured":"Ghanim V., Herrmann H., Heller G. et al. 5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand. Blood 2012; 119 (18): 4242-4252.","DOI":"10.1182\/blood-2011-09-382770"}],"container-title":["Terapevticheskii arkhiv"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T19:34:22Z","timestamp":1718480062000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.mediasphera.ru\/issues\/terapevticheskij-arkhiv\/2014\/12\/downloads\/ru\/030040-366020141223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014]]}},"alternative-id":["terarkh20148612127-134"],"URL":"https:\/\/doi.org\/10.17116\/terarkh20148612127-134","relation":{},"ISSN":["0040-3660"],"issn-type":[{"value":"0040-3660","type":"print"}],"subject":[],"published":{"date-parts":[[2014]]}}}